Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA2 | P00918 | 11/20 | 0.44 |
| ▸ | ADH1B | P00325 | 2/20 | 0.32 |
| ▸ | ADH1A | P07327 | 2/20 | 0.32 |
| ▸ | ADH7 | P40394 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 8/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA7 | P43166 | 3/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | ADH1C | P00326 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28043868 | 0.98 | CA1 (0.43) | CA1CA2ADH1BADH1AADH7 | |
| SCHEMBL28192511 | 0.98 | CA1 (0.43) | CA1CA2ADH1BADH1AADH7 | |
| Ammonia Solution, Strong SCHEMBL28193056 | 0.98 | CA1 (0.43) | CA1CA2ADH1BADH1AADH7 | |
| SCHEMBL9298738 | 0.81 | — | — | |
| SCHEMBL28204157 | 0.80 | CA1 (0.43) | CA1CA2CA9 | |
| SCHEMBL28101000 | 0.78 | CA1 (0.41) | CA1CA2 | |
| SCHEMBL9410140 | 0.73 | — | — | |
| SCHEMBL28781975 | 0.71 | — | — | |
| SCHEMBL11466931 | 0.71 | — | — | |
| SCHEMBL28265900 | 0.71 | CA1 (0.48) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109082688-B | A kind of lithium battery two-sided optical ultrathin electrolytic copper foil and preparation method thereof | 浙江永太科技股份有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-109863261-A | The zero defect fill method of silicon through electrode and copper plating bath for the fill method | 韩国生产技术研究院 | 2019-06-07 | — | — | CN | claimed |
| CN-109082688-A | A kind of lithium battery two-sided optical ultrathin electrolytic copper foil and preparation method thereof | 浙江永太科技股份有限公司 | 2018-12-25 | — | — | CN | claimed |
| CN-105887144-B | Copper electrolyte and its copper plating process is electroplated | 广东光华科技股份有限公司 | 2018-09-21 | — | — | CN | claimed |
| CN-110396704-A | A kind of ultrathin electrolytic copper foil and preparation method | HUBEI ZHONGYI TECH CO LTD | 2019-11-01 | — | — | CN | disclosed |
| CN-109082688-B | A kind of lithium battery two-sided optical ultrathin electrolytic copper foil and preparation method thereof | 浙江永太科技股份有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-109863261-A | The zero defect fill method of silicon through electrode and copper plating bath for the fill method | 韩国生产技术研究院 | 2019-06-07 | — | — | CN | disclosed |
| CN-109082688-A | A kind of lithium battery two-sided optical ultrathin electrolytic copper foil and preparation method thereof | 浙江永太科技股份有限公司 | 2018-12-25 | — | — | CN | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | CA1 2538/4885CA2 1703/4885ADH1B 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.